FY2024 Earnings Estimate for Certara Issued By William Blair

Certara, Inc. (NASDAQ:CERT) – Equities researchers at William Blair upped their FY2024 earnings estimates for shares of Certara in a research note issued on Wednesday, January 15th. William Blair analyst M. Smock now expects that the company will post earnings of $0.28 per share for the year, up from their previous estimate of $0.27. The consensus estimate for Certara’s current full-year earnings is $0.28 per share.

Certara (NASDAQ:CERT) last posted its earnings results on Wednesday, November 6th. The company reported $0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.11 by $0.02. The company had revenue of $94.80 million during the quarter, compared to the consensus estimate of $95.51 million. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The firm’s quarterly revenue was up 10.7% on a year-over-year basis. During the same period in the previous year, the firm posted $0.06 earnings per share.

CERT has been the subject of several other reports. Robert W. Baird reduced their price target on Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a research report on Tuesday, November 5th. Barclays cut their target price on shares of Certara from $14.00 to $12.00 and set an “equal weight” rating for the company in a report on Thursday, November 7th. Finally, UBS Group raised shares of Certara from a “neutral” rating to a “buy” rating and set a $16.00 price target on the stock in a report on Friday, September 27th. Six analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $15.92.

Certara Stock Performance

Shares of CERT stock opened at $11.76 on Friday. Certara has a 52-week low of $9.41 and a 52-week high of $19.87. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28. The stock has a market cap of $1.89 billion, a PE ratio of -58.80, a price-to-earnings-growth ratio of 4.55 and a beta of 1.52. The business has a 50-day simple moving average of $10.88 and a 200-day simple moving average of $11.95.

Hedge Funds Weigh In On Certara

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Brown Brothers Harriman & Co. acquired a new position in shares of Certara during the 3rd quarter worth about $27,292,000. Sei Investments Co. boosted its stake in shares of Certara by 39.5% in the second quarter. Sei Investments Co. now owns 997,871 shares of the company’s stock worth $13,821,000 after acquiring an additional 282,357 shares during the last quarter. Kopion Asset Management LLC lifted its holdings in Certara by 46.0% in the 4th quarter. Kopion Asset Management LLC now owns 555,643 shares of the company’s stock valued at $5,918,000 after purchasing an additional 175,005 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its stake in Certara by 40.7% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,901,898 shares of the company’s stock worth $45,691,000 after purchasing an additional 1,128,006 shares during the last quarter. Finally, Daventry Group LP grew its holdings in shares of Certara by 153.0% during the second quarter. Daventry Group LP now owns 1,308,572 shares of the company’s stock worth $18,124,000 after buying an additional 791,405 shares in the last quarter. 73.96% of the stock is owned by hedge funds and other institutional investors.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.